EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Wagner, AD, Grabsch, HI orcid.org/0000-0001-9520-6228, Mauer, M et al. (12 more authors) (2019) EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 19. 494. ISSN 1471-2407

Abstract

Metadata

Authors/Creators:
  • Wagner, AD
  • Grabsch, HI https://orcid.org/0000-0001-9520-6228
  • Mauer, M
  • Marreaud, S
  • Caballero, C
  • Thuss-Patience, P
  • Mueller, L
  • Elme, A
  • Moehler, MH
  • Martens, U
  • Kang, Y-K
  • Rha, SY
  • Cats, A
  • Tokunaga, M
  • Lordick, F
Copyright, Publisher and Additional Information: © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Gastric cancer; Gastro-esophageal junction cancer; Perioperative chemotherapy; Trastuzumab; Pertuzumab; HER2
Dates:
  • Published: 24 May 2019
  • Accepted: 3 May 2019
  • Published (online): 24 May 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 23 Sep 2019 10:00
Last Modified: 23 Sep 2019 11:02
Status: Published
Publisher: BMC
Identification Number: https://doi.org/10.1186/s12885-019-5675-4
Related URLs:

Download

Share / Export

Statistics